These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Olfactory groove meningioma: discussion of clinical presentation and surgical outcomes following excision via the subcranial approach. Pepper JP; Hecht SL; Gebarski SS; Lin EM; Sullivan SE; Marentette LJ Laryngoscope; 2011 Nov; 121(11):2282-9. PubMed ID: 21994142 [TBL] [Abstract][Full Text] [Related]
23. Early postoperative radiotherapy improves progression free survival in patients with grade 2 meningioma. Aboukais R; Baroncini M; Zairi F; Reyns N; Lejeune JP Acta Neurochir (Wien); 2013 Aug; 155(8):1385-90; discussion 1390. PubMed ID: 23728501 [TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. Chamberlain MC J Neurooncol; 2012 Apr; 107(2):315-21. PubMed ID: 22127733 [TBL] [Abstract][Full Text] [Related]
25. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730 [TBL] [Abstract][Full Text] [Related]
26. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Bartolomei M; Bodei L; De Cicco C; Grana CM; Cremonesi M; Botteri E; Baio SM; Aricò D; Sansovini M; Paganelli G Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1407-16. PubMed ID: 19319527 [TBL] [Abstract][Full Text] [Related]
27. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530 [TBL] [Abstract][Full Text] [Related]
29. Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. Peyre M; Zanello M; Mokhtari K; Boch AL; Capelle L; Carpentier A; Clemenceau S; Karachi C; Navarro S; Nouet A; Reina V; Valery CA; Sanson M; Cornu P; Kalamarides M J Neurooncol; 2015 May; 123(1):151-60. PubMed ID: 25894596 [TBL] [Abstract][Full Text] [Related]
30. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326 [TBL] [Abstract][Full Text] [Related]
31. Use of 111In-pentetreotide scan in a subject with treatment refractory atypical meningioma. Bural GG; Lieberman F; Mountz JM Clin Nucl Med; 2014 Apr; 39(4):342-5. PubMed ID: 24445268 [TBL] [Abstract][Full Text] [Related]
32. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Hrachova M; Nguyen ENT; Fu BD; Dandekar MJ; Kong XT; Cadena G; Hsu FPK; Billimek J; Taylor TH; Bota DA Front Neurol; 2020; 11():373. PubMed ID: 32435228 [No Abstract] [Full Text] [Related]
33. Treatment of high risk or recurrent meningiomas with hydroxyurea. Rosenthal MA; Ashley DL; Cher L J Clin Neurosci; 2002 Mar; 9(2):156-8. PubMed ID: 11922703 [TBL] [Abstract][Full Text] [Related]
34. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767 [TBL] [Abstract][Full Text] [Related]
35. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. Chamberlain MC CNS Oncol; 2013 May; 2(3):227-35. PubMed ID: 25054463 [TBL] [Abstract][Full Text] [Related]
36. Comparison of tc-99m depreotide and in-111 octreotide in recurrent meningioma. Hellwig D; Samnick S; Reif J; Romeike BF; Reith W; Moringlane JR; Kirsch CM Clin Nucl Med; 2002 Nov; 27(11):781-4. PubMed ID: 12394124 [TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. Klutmann S; Bohuslavizki KH; Brenner W; Behnke A; Tietje N; Kröger S; Hugo HH; Mehdorn HM; Clausen M; Henze E J Nucl Med; 1998 Nov; 39(11):1913-7. PubMed ID: 9829583 [TBL] [Abstract][Full Text] [Related]
38. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219 [TBL] [Abstract][Full Text] [Related]
39. Intracranial meningeal hemangiopericytoma: 10 years experience of a tertiary care Institute. Kumar N; Kumar R; Kapoor R; Ghoshal S; Kumar P; Salunke PS; Radotra BD; Sharma SC Acta Neurochir (Wien); 2012 Sep; 154(9):1647-51. PubMed ID: 22790838 [TBL] [Abstract][Full Text] [Related]